Publication Name	World Journal of Cardiology
Manuscript ID	31152
Country	United States

Received	2016-11-01 09:03
Peer-Review Started	2016-11-04 08:28
To Make the First Decision	2016-12-14 08:44
Return for Revision	2016-12-15 11:46
Revised	2016-12-26 16:55
Second Decision	2017-01-10 17:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-01-18 10:11
Articles in Press	2017-01-18 10:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-02-20 13:26
Publish the Manuscript Online	2017-02-23 11:56

ISSN	1949-8462 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Meta-Analysis
Article Title	Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Mahesh Anantha Narayanan, Yogesh NV Reddy, Janani Baskaran, Abhishek Deshmukh, David G Benditt and Ganesh Raveendran
Funding Agency and Grant Number
Corresponding Author	Mahesh Anantha Narayanan, MD, Division of Cardiovascular Diseases, University of Minnesota Medical Center, 500 SE Harvard Street, Minneapolis, MN 55455, United States. manantha@umn.edu
Key Words	Ivabradine; Heart failure
Core Tip	Ivabradine was recently given a class IIa indication in the 2016 focused update on systolic heart failure in the ACC/AHA/HFSA guidelines. But it is unclear whether ivabradine offers any additional benefit over and above that offered by beta blockers. Our analysis showed lower heart rate and combined end point of cardiac death and heart failure hospitalization at follow-up with ivabradine combined with beta blocker compared to beta blocker alone. Combined therapy did not improve cardiovascular mortality, all cause mortality or heart failure hospitalization. Further studies are essential before widespread use of combination therapy with ivabradine can be recommended.
Publish Date	2017-02-23 11:56
Citation	Anantha Narayanan M, Reddy YNV, Baskaran J, Deshmukh A, Benditt DG, Raveendran G. Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis. World J Cardiol 2017; 9(2): 182-190
URL	http://www.wjgnet.com/1949-8462/full/v9/i2/182.htm
DOI	http://dx.doi.org/10.4330/wjc.v9.i2.182

Full Article (PDF)	WJC-9-182.pdf
Full Article (Word)	WJC-9-182.doc
Manuscript File	31152-Review.docx
Answering Reviewers	31152-Answering reviewers.pdf
Audio Core Tip	31152-Audio core tip.wav
Biostatistics Review Certificate	31152-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	31152-Conflict-of-interest statement.pdf
Copyright License Agreement	31152-Copyright assignment.pdf
Supplementary Material	31152-Supplementary material.docx
Peer-review Report	31152-Peer-review(s).pdf
Scientific Misconduct Check	31152-Scientific misconduct check.pdf
Scientific Editor Work List	31152-Scientific editor work list.pdf